Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study
Journal of Thoracic Oncology(2023)
Abstract
As first-line therapy for EGFR mutation-positive lung cancer, the combination of erlotinib and ramucirumab has been shown to prolong PFS compared with erlotinib alone and is one of the standard treatments, but its efficacy in patients previously treated with EGFR-TKI is unknown.
MoreTranslated text
Key words
EGFR,Erlotinib,Ramucilumab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined